Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LRCX
6. LVS
7. SAP
8. CSX
9. SPY
10. KNX

Go back to Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Pliant Therapeutics (PLRX) PT Lowered to $45 at RBC Capital

May 7, 2024 6:19 AM EDT

RBC Capital analyst Brian Abrahams lowered the price target on Pliant Therapeutics (NASDAQ: PLRX) to $45.00 (from $54.00) while maintaining a Outperform rating.

The analyst comments "PLRX's IPF program remains on track with the ph.IIb expected to complete enrollment 1Q25. While this likely... More

Pliant Therapeutics (PLRX) PT Lowered to $44 at Citi

May 7, 2024 5:46 AM EDT

Citi analyst David Lebowitz lowered the price target on Pliant Therapeutics (NASDAQ: PLRX) to $44.00 (from $45.00) while maintaining a Buy rating.

The analyst comments "Pliant reported 1Q24 financial results and provided an update on the status of its pipeline programs. Over the... More